Observational studyBMC psychiatry2025
Gender-specific associations of blood immune markers with symptoms and cognitive function in major depressive disorder: a cross-sectional observational study.
Observational study in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCognitive impairments constitute a core manifestation of major depressive disorder (MDD), albeit the precise mechanisms governing these impairments remain elusive. Inflammation may contribute to cognitive impairment and clinical symptoms in MDD. We conducted an investigation into the inflammatory markers present in patients with MDD, including white blood cell (WBC) counts, monocytes, lymphocytes, neutrophils, platelets, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR), and their associations with symptoms and cognitive performance.
methodsA cohort comprising 95 patients diagnosed with MDD and 65 healthy controls (HCs) was enrolled. Clinical symptomatology was evaluated utilizing the Hamilton Depression Rating Scale (HAMD) and the Hamilton Anxiety Rating Scale (HAMA). Cognitive performance was evaluated using the THINC-Integrated Tool (THINC-it), whereas inflammatory markers were measured via complete blood count (CBC). Multiple linear regression analyses investigated correlations of CBC indicators with symptoms and cognitive performance.
resultsPatients with MDD exhibited cognitive impairments and elevated WBC, lymphocyte, monocyte, and MLR levels compared with those of the HCs. WBC and PLR negatively correlated with HAMD and HAMA scores, respectively. MLR was positively correlated with HAMD scores of female patients; it was negatively correlated with cognitive performance. Gender-specific analyses revealed distinct patterns among male and female patients.
conclusionImmune dysregulation in MDD was associated with emotional symptoms and cognitive impairment. Inflammatory markers correlated with attention, executive function and working memory in males, whereas in females, they were linked to subjective cognition, executive function, and composite cognition. Gender differences should be considered in immune-cognitive interactions, which may inform personalized therapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.